Form 4: Nuvalent's Chief Legal Officer, Deborah Ann Miller, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 4, 2024, Deborah Ann Miller, the Chief Legal Officer of Nuvalent, Inc., executed a transaction involving the company's stock.
• Miller exercised a stock option to acquire 3,000 shares of Class A Common Stock at a price of $6.89 per share.
• Concurrently, Miller sold a total of 2,998 shares of Class A Common Stock in multiple transactions at weighted average prices ranging from $71.54 to $74.81.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Miller directly owns 33,300 shares of Class A Common Stock and holds options for 188,608 shares.
• The stock options vest over time, with 25% vesting on April 15, 2022, and the remainder vesting in equal monthly installments over the subsequent three years, contingent upon continued service to Nuvalent, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There's no indication of unusual activity or significant shifts in insider holdings.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in trading activities by company insiders. These filings are closely watched by investors to gauge insider sentiment and potential future stock performance.

Comparison to Industry Standards

• Insider selling is a common practice, especially among executives who receive stock options as part of their compensation.
• The use of Rule 10b5-1 trading plans is a standard method to avoid accusations of insider trading, as these plans are established in advance and operate independently of any material non-public information.
• Comparing Miller's transactions to those of other executives in similar biotech companies would require analyzing their Form 4 filings and compensation structures.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an insider, but the pre-arranged trading plan mitigates concerns about opportunistic trading.
• Employees may view the transactions as a standard part of executive compensation.

Key Dates